Navigation Links
Hypercholesterolemia in Medical News

FDA Approves LIVALO(R) for Primary Hypercholesterolemia and Combined Dyslipidemia

MONTGOMERY, Ala. and MORRISVILLE, N.C., Aug. 3 /PRNewswire/ -- Kowa Research Institute (KRI) based in Morrisville, NC and Kowa Pharmaceuticals America, Inc. (KPA), a privately-held specialty pharmaceutical company headquartered in Montgomery, AL, announced today that the U.S. ...

Genes Linked to Cholesterol in Cells Are Identified

...fore, some of the genes identified by us as regulators of cellular cholesterol in future studies might turn out to be disease genes that contribute to hypercholesterolemia [high cholesterol] in some cases." The genes identified in the study may also have potential as targets for new cholesterol-lowering drugs, the res...

Isis Reports Strong Financial Results and Highlights for First Quarter of 2009

...study evaluating mipomersen in homozygous Familial hypercholesterolemia (FH) patients and from additional mipomersen studi...study evaluating mipomersen in homozygous Familial hypercholesterolemia patients. We expect top-line data from this study...ed a Phase 3 study evaluating mipomersen in severe hypercholesterolemia patients. This latest mipomersen study is the fou...

Sanofi-aventis Announces Good First-quarter 2009 Performance

... Phase III, saredutant is discontinued on the basis of results from the study in association with escitalopram in depression, AVE5530 is halted in hypercholesterolemia due to insufficient efficacy, and the rights to TroVax (R) are returned to Oxford BioMedica. As regards vaccines, resources in the intercontinental z...

Isis Reports Strong Financial Results and Highlights for Fiscal Year 2008

...study evaluating mipomersen in homozygous Familial hypercholesterolemia (FH) patients and from additional mipomersen studi...e 3 studies in heterozygous FH subjects, high-risk hypercholesterolemia and severe hypercholesterolemia patients and a Phase 2 study in statin-intolerant ...

BioMed Realty Trust's Center for Life Science Boston Now 91% Leased

... business, Kowa is responsible for sales and marketing of innovative drugs and focuses on promoting cardiovascular drugs, such as a treatment drug for hypercholesterolemia and hypertension through its owned subsidiary, Kowa Pharmaceutical Co. Ltd. In addition, Kowa has focused on lifestyle diseases (arteriosclerosis, kid...

Studies Challenge Framingham Risk Score

...ramingham Risk Score is validated up to age 75. There have been signs in the medical literature that the classic risk factors such as hypertension and hypercholesterolemia [high cholesterol levels] were not performing that well for people with advanced age." The new study "indicates that the traditional risk factors b...

AAO-SOE Joint Meeting Nov. 9 glaucoma research highlights

... with progressive or asymmetric glaucoma despite normal eye pressure---especially in the presence of cardiovascular risk factors such as hypertension, hypercholesterolemia or ischemia heart disease---for carotid artery Doppler scan to pick up those who could be at high risk for stroke and may benefit from carotid artery ...

Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets

...t from Tulane University published on American Heart Association's Journal of Circulation shows that due to lifestyle changes in China, high levels of hypercholesterolemia and low levels of awareness, treatment, and information regarding same has made cardiovascular disease the leading cause of death in China. As a leadi...

Lipid Association Responds to New Cholesterol Guidelines for Children

...that this is a health concern only for middle-aged and elderly persons. In some affected children, such as those with the inherited disorder, familial hypercholesterolemia (FH), or in those whose parent suffered coronary artery disease (CAD) before 50 years of age, atherosclerosis progresses more rapidly, leading to hear...
Hypercholesterolemia in Medical Technology

Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia

First Presentation of Pivotal Study Data in Pediatric Patients Presented at the American Heart Association's Annual Scientific Sessions 2008 PARSIPPANY, N.J., Nov. 11 /PRNewswire-FirstCall/ -- Daiichi Sankyo, Inc. (DSI), announced today that results from the pivotal study supporting the use ...

Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients Presented at ACC

* Homozygous FH patients already being treated with maximally tolerated lipid-lowering therapies experienced 50% further reductions in LDL-C with similar reductions in other atherogenic when treated with 300 mg/week ISIS 301012 NEW ORLEANS, and CARLSBAD, Calif., March 26, 2007 /PRNewswire-FirstCal...

Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients

* Treatment with ISIS 301012 produced at least 45% additional reduction in patients' LDL-cholesterol when added to maximally-tolerated lipid-lowering therapies CARLSBAD, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced updated results from its ongoing Phase 2 cli...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...full data from a Phase 3 study evaluating mipomersen in homozygous Familial hypercholesterolemia (FH) patients; positive top line data was reported in May 2009 Report...filing in Europe shortly afterwards. Data from our Phase 3 study in severe hypercholesterolemia patients should be available at the time of these U.S. submissions and may ...

Study Demonstrates Efficacy of Pitavastatin in Elderly Patients

...sterol in a group of elderly patients with primary hypercholesterolemia or combined dyslipidemia," said Professor Steen St...s aged more than or equal to 65 years with primary hypercholesterolemia or combined dyslipidemia. About half of the patien... suitable statin for elderly patients with primary hypercholesterolemia or combined dyslipidemia who are taking other medi...

Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen

... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced that they have begun a phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH), a genetic disorder that causes exceptionally high levels of LDL cholesterol. It is the first of four new trials the companies plan to initiate...

New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer

... with interferon-alpha. TORISEL also was associated with the development of hypercholesterolemia of grade 2 or higher, compared with interferon-alpha (P=0.001), but there w...us interferon-alpha (P=0.675). However, the development of hyperglycemia or hypercholesterolemia did not have affect on overall survival or progression-free survival in thi...

Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months

... 2 open-label extension (OLE) study of mipomersen in patients with familial hypercholesterolemia (FH). In FH patients exposed to mipomersen for as long as 16 months, the sa...th high cholesterol at high risk of cardiovascular events. ABOUT FAMILIAL hypercholesterolemia (FH) FH patients have high blood concentrations of LDL-cholesterol due to...

ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial

...fects of the highest approved dose of VYTORIN/INEGY versus the highest approved dose of simvastatin 80 mg alone in patients with Heterozygous Familial hypercholesterolemia (HeFH). The study was made public by Merck/Schering-Plough Pharmaceuticals. "The debate around the clinical study on cholesterol drugs has received ...

New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease

...ined to prevent heart disease, heart attacks, or strokes. For patients with hypercholesterolemia and mixed dyslipidemia, the usual recommended starting dose of CRESTOR is 1...nts, and patients with severe renal insufficiency. For patients with marked hypercholesterolemia (LDL-C >190 mg/dL) and aggressive lipid targets, a 20-mg starting dose may ...
Hypercholesterolemia in Medical Definition

Pathology

...sease ) Other lipid Lipoprotein/lipidemias: Hyperlipidemia - hypercholesterolemia - Familial hypercholesterolemia - Xanthoma - Combined hyperlipidemia - Lecithin cholesterol acyltrans...
Hypercholesterolemia in Medical Dictionary

Familial Hypercholesterolemia

Familial hypercholesterolemia is a genetic disorder characterized by high cholesterol levels, specifically very high low-density lipoprotein levels, in the blood and early cardiovascular disease. Many patients have mutations... Hypercholesterolemia is the presence of high levels o...

High Cholesterol

... hypercholesterolemia is the presence of high levels of cholesterol in the blood. It is not a disease but a metabolic derangement that can be secondary to many diseas...
Hypercholesterolemia in Biological Technology

Isis Reports Financial Results and Highlights for Third Quarter of 2008

...atients and high-risk high cholesterol patients -- Report top line data on mipomersen from a Phase 2 liver imaging study in heterozygous Familial hypercholesterolemia (FH) patients -- Provide an update on mipomersen from an ongoing open-label extension study in patients with FH -- Report Phase 2 study data in ...

Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)

...gy to lower Total-C and LDL-C to target levels. CRESTOR has not been determined to prevent heart disease, heart attacks, or strokes. For patients with hypercholesterolemia and mixed dyslipidemia, the usual recommended starting dose of CRESTOR is 10 mg. The 40-mg dose of CRESTOR is reserved only for those patients who hav...

Isis Reports Financial Results and Highlights for Second Quarter of 2008

...cial performance." Upcoming Key Milestones -- Initiate three trials in addition to the Phase 3 study in patients with heterozygous Familial hypercholesterolemia (FH) announced this week, studying mipomersen in apheresis-eligible patients and high-risk high cholesterol patients -- Present liver imag...

Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management

...lone has been inadequate, to reduce elevated total cholesterol, LDL- C, Apo B, and triglyceride levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. In patients with a history of myocardial infarction and hypercholesterolemia, niacin is indicated to reduce the risk of recurr...

Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy

...s in the prevention of coronary disease, the nation's top killer. "Atherotech believes that precise physician decisions about lifelong management of hypercholesterolemia can only be accomplished with a detailed profiling of lipoprotein components," said Atherotech Chief Medical Officer James Ehrlich, M.D. "By identifyi...

Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen

...ce under the Hart-Scott-Rodino Antitrust Improvements Act. About Familial hypercholesterolemia (FH) FH patients have high blood concentrations of LDL-cholesterol due to... of premature cardiovascular diseases (CVD) and CVD-related death. Familial hypercholesterolemia can be present in two forms: homozygous (hoFH), where the same defective ge...

Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections

... in the treatment of diseases, the etiology of which is misrouted or misfolded proteins, for example, cystic fibrosis, nephrogenic diabetes insipidus, hypercholesterolemia and others. Axentis is managed by a team of experienced entrepreneurs. About aRigen Pharmaceuticals, Inc. ( http://www.arigen.jp ) aRigen Pharmace...

Genzyme Launches Cholestagel(R) in Europe

... New Therapy Helps Lower Cholesterol in Primary hypercholesterolemia Patients CAMBRIDG...gel as an add-on therapy in patients with familial hypercholesterolemia (FH) -- an inherited disorder that causes exceptio...s with peripheral arterial disease. About Primary hypercholesterolemia Primary...

New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition

...cated alone or in combination with a statin, as an adjunct to diet and exercise for the reduction of elevated LDL cholesterol in patients with primary hypercholesterolemia (Fredrickson Type IIa) when the response to diet and exercise has been inadequate. Liver- function monitoring is not required with WelChol when used a...
Other Tags
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience ... business has introduced its new collection of 2015 prom ... The new prom outfits are guaranteed to contain the ... are specially designed for 2015. Anyone who wants to ... its website before Jan. 26, 2015, the deadline of ...
(Date:12/25/2014)... North Carolina (PRWEB) December 25, 2014 ... North Carolina Retirement Community, recently showed their generous ... girls of the Catawba County Parenting Network- Grandparents ... the 10 children gathered around the largest Christmas ... to open presents purchased by residents of the ...
(Date:12/24/2014)... 25, 2014 Over 700 toys, that’s ... local communities. That is 700 smiling little faces this ... Additionally over $6000 in monetary donations was given to ... of the expenses they incur through the year. Some ... A Child's Haven , Shrine's Children's Hospitals, Toys ...
(Date:12/24/2014)... York (PRWEB) December 24, 2014 Risperdal ... in a mass tort litigation currently underway in Pennsylvania’s ... As of December 24, 2014, court documents indicate ... on behalf of individuals who developed gynecomastia (male breast ... Data from the Court indicates that this represents an ...
Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
Other Contents